A safe and potent anti-CD19 CAR T cell therapy-Reference-Cited by-同舟云学术

A safe and potent anti-CD19 CAR T cell therapy

Published:2019-04-22 Issue:6 Volume:25 Page:947-953
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Ying Zhitao,Huang Xue F.,Xiang Xiaoyu,Liu Yanling,Kang Xi,Song Yuqin,Guo Xiaokai,Liu Hanzhi,Ding Ning,Zhang Tingting,Duan Panpan,Lin Yufu,Zheng Wen,Wang Xiaopei,Lin Ningjing,Tu Meifeng,Xie Yan,Zhang Chen,Liu Weiping,Deng Lijuan,Gao Shunyu,Ping Lingyan,Wang Xuejuan,Zhou Nina,Zhang Junqing,Wang Yulong,Lin Songfeng,Mamuti Mierzhati,Yu Xueyun,Fang Lizhu,Wang Shuai,Song Haifeng,Wang Guan,Jones Lindsey,Zhu Jun^ORCID,Chen Si-Yi^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

http://www.nature.com/articles/s41591-019-0421-7.pdf

Reference40 articles.

1. Imai, C. et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18, 676–684 (2004).

2. Campana, D., Schwarz, H. & Imai, C. 4-1BB chimeric antigen receptors. Cancer J. 20, 134–140 (2014).

3. Milone, M. C. et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol. Ther. 17, 1453–1464 (2009).

4. Porter, D. L., Levine, B. L., Kalos, M., Bagg, A. & June, C. H. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365, 725–733 (2011).

5. Maude, S. L. et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371, 1507–1517 (2014).

Cited by 340 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting cytokine networks in neuroinflammatory diseases;Nature Reviews Drug Discovery;2024-09-11

2. Photonanozyme–Kras–ribosome combination treatment of non-small cell lung cancer after COVID-19;Frontiers in Immunology;2024-09-06

3. Exosomes-based immunotherapy for cancer: Effective components in the naïve and engineered forms;International Immunopharmacology;2024-09

4. The interplay between persistent pathogen infections with tumor microenvironment and immunotherapy in cancer;Cancer Medicine;2024-09

5. A multi-scale semi-mechanistic CK/PD model for CAR T-cell therapy;Frontiers in Systems Biology;2024-08-29